Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 383, Issue 6, 2011, Pages 627-633

  Müller, Thomas ^a,b   Woitalla, Dirk ^b   Muhlack, Siegfried ^b  

^a St Joseph Hospital   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Absorption; Homocysteine; Levodopa; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; HOMOCYSTEINE; METHIONINE; METHYL GROUP;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PROTEIN DEGRADATION; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOPA DECARBOXYLASE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TYROSINE;

EID: 79959375134     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0629-7     Document Type: Article

References (21)

1. Y Ben Shlomo MG Marmot 1995 Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58 293 299 7897409 10.1136/jnnp.58.3.293 1:STN:280: DyaK2M3gsFWnug%3D%3D
2. P Benetello M Furlanut M Fortunato F Pea M Baraldo 1997 Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association Pharmacol Res 35 313 315 9264047 10.1006/phrs.1997.0145 1:CAS:528: DyaK2sXls1yhsbY%3D (Pubitemid 27331190)
3. D Caccamo G Gorgone M Curro G Parisi IW Di C Menichetti V Belcastro L Parnetti A Rossi F Pisani R Ientile P Calabresi 2007 Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients Neuromolecular Med 9 249 254 17914182 10.1007/s12017-007-8006-x 1:CAS:528:DC%2BD2sXhtV2gt7jI (Pubitemid 350129699)
4. F Cacciapuoti 2011 Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties J Thromb Thrombolysis 10.1007/s11239-011-0550-4 21234645
5. M Kuoppamaki K Korpela R Marttila V Kaasinen P Hartikainen J Lyytinen S Kaakkola J Hanninen E Loyttyniemi M Kailajarvi P Ruokoniemi J Ellmen 2009 Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily Eur J Clin Pharmacol 65 443 455 19229530 10.1007/s00228-009- 0622-y
6. P Lamberti S Zoccolella G Iliceto E Armenise A Fraddosio M de Mari P Livrea 2005 Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients Mov Disord 20 69 72 15390046 10.1002/mds.20261 (Pubitemid 40277507)
7. JW Miller B Shukitt-Hale R Villalobos-Molina MR Nadeau J Selhub JA Joseph 1997 Effect of Levodopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats Clin Neuropharmacol 20 55 66 9037574 10.1097/00002826-199702000-00007 1:CAS:528:DyaK2sXmt1Oitbc%3D (Pubitemid 27098356)
8. T Muller 2010 Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms Int Rev Neurobiol 95 49 71 21095459 10.1016/B978-0-12-381326-8.00004-1
9. T Muller 2010 The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease Clinical Medicine Insights: Therapeutics 2 155 168 10.4137/CMT.S1169
10. T Muller W Kuhn 2006 Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients Eur J Clin Pharmacol 62 447 450 16758261 10.1007/s00228-006-0132-0 (Pubitemid 43873716)
11. T Muller W Kuhn 2009 Homocysteine levels after acute levodopa intake in patients with Parkinson's disease Mov Disord 24 1339 1343 19425084 10.1002/mds.22607
12. T Muller S Muhlack 2009 Peripheral COMT inhibition prevents levodopa associated homocysteine increase J Neural Transm 116 1253 1256 19657587 10.1007/s00702-009-0275-0
13. T Muller S Muhlack 2010 Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease Parkinsonism Relat Disord 16 688 689 20719554 10.1016/j.parkreldis.2010.07.012
14. T Muller C Erdmann S Muhlack D Bremen H Przuntek O Goetze D Woitalla 2006 Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease J Neural Transm 113 1441 1448 16604302 10.1007/s00702-006-0442-5 1:STN:280:DC%2BD28rmt1GnsA%3D%3D (Pubitemid 44435882)
15. T Muller C Jugel R Ehret G Ebersbach G Bengel S Muhlack F Klostermann 2011 Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel J Neural Transm 10.1007/s00702-011-0614-9
16. K Nakaso K Yasui H Kowa M Kusumi K Ueda Y Yoshimoto T Takeshima K Sasaki K Nakashima 2003 Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with levodopa, homocysteine, and MTHFR genotype J Neurol Sci 207 19 23 12614926 10.1016/S0022-510X(02)00353-2 1:CAS:528:DC%2BD3sXhsVCltbw%3D (Pubitemid 36287098)
17. M Nevrly P Kanovsky H Vranova K Langova P Hlustik 2010 Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients Neurol Sci 31 565 569 20464572 10.1007/s10072-010-0262-0
18. E Nissinen H Nissinen H Larjonmaa A Vaananen T Helkamaa I Reenila P Rauhala 2005 The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats J Neural Transm 112 1213 1221 15614425 10.1007/s00702-004-0262-4 1:CAS:528:DC%2BD2MXpsVClsL8%3D (Pubitemid 41215924)
19. RB Postuma AJ Espay C Zadikoff O Suchowersky WR Martin AL Lafontaine R Ranawaya R Camicioli AE Lang 2006 Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study Neurology 66 1941 1943 16801668 10.1212/01.wnl.0000219815.83681.f7 1:CAS:528:DC%2BD28XlsFKlu7s%3D (Pubitemid 44049836)
20. P Valkovic J Benetin P Blazicek L Valkovicova K Gmitterova P Kukumberg 2005 Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients Parkinsonism Relat Disord 11 253 256 15878587 10.1016/j.parkreldis. 2005.01.007 (Pubitemid 40692838)
21. TA Zesiewicz L Wecker KL Sullivan LR Merlin RA Hauser 2006 The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status Clin Neuropharmacol 29 106 111 16772808 10.1097/01.WNF.0000220817.94102.95 1:CAS:528:DC%2BD28XlsFeju7c%3D (Pubitemid 44503887)